



Inify
Laboratories

Inify Laboratories

Interim report for the third quarter 2026

This is Inify Laboratories



Who we are

Inify Laboratories is based in Sweden and its shares are listed on Euronext Growth Oslo. The company has two subsidiaries; Inify Laboratories Nordics AB and Inify Laboratories Ltd.



How we do it

Inify has built a unique and ultramodern laboratory and developed a fully digital, standardized and AI-assisted workflow in order to optimize quality and shorten response times. The diagnostic services is offered for selected cancer types, where specialization contributes to high and reliable quality.



What we do

Inify Laboratories provides cancer diagnostics in histopathology. Our laboratory offers diagnostic services to both public and private healthcare providers. The business model and technical structure allow for scalability in volume, diagnosis and geographical expansion.



Why we do it

Clinical pathology is currently under great pressure, with high workloads and limited – even declining – resources. An aging population, increasing cancer incidence, and more frequent examinations and screening programmes further increase the workload. Solving the problem through labor alone is not an option, it is necessary to work in new ways.

Our vision:

World leading diagnostics for everyone!

Third quarter highlights

- Sales 5.2 MSEK (5.0)
- Clinical diagnostics established in the UK
- Diagnostic quality confirmed in research reports

Key figures	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Average number of shares	107 474 845	62 070 083	84 772 464	62 070 083	62 070 083
Earnings per share (SEK)	-0.18	-0.19	-0.59	-0.60	-0.86
Solidity	89.5%	83.1%	89.5%	83.1%	75.8%
Sales (TSEK)	5 238	4 991	19 168	15 772	22 228
EBITDA (TSEK)	-16 674	-13 827	-52 910	-44 948	-64 797
Cash at period end	72 268	112 156	72 268	112 156	57 532

The company use some figures that are considered as Alternative Performance Measures.
Please see description under section Alternative Performance Measures and Definitions.



Letter from the CEO

UK diagnostics established – continued customer dialogues and confirmed exceptional diagnostic quality

We are clearly noticing increased interest in Inify and our diagnostic services as new agreements are put in place. This is especially true in the UK, where we have made significant progress in dialogues with several hospitals across different regions.

Sales in the quarter were impacted by the vacation season as expected and are slightly lower than in the previous quarter. At the same time, we are making clear progress and strengthening our position in the market, reinforcing our confidence in growth going forward.

United Kingdom

During the quarter, we successfully delivered our services on a regular basis to University Hospital Plymouth NHS Trust (UHP), and the establishment team has now handed over operations to our local laboratory team. Feedback from the diagnosticians working in the system has been very positive. This lays the foundation for increasing our share of the hospital's total sample volume in accordance with the agreed evaluation plan.

The agreement with UHP has caught attention in the UK market and contributed to a clear increase

in interest from several hospitals around the country. It has both advanced existing dialogues and created new opportunities.

The fact remains that most hospitals in the country face significant challenges in meeting the requirements for effective pathways for patients undergoing investigation for prostate cancer. This is where our unique end-to-end solution comes in, offering the potential to solve these challenges in close collaboration with each hospital.

The process of entering into evaluation agreements within the NHS is complex and involves many stakeholders within the hospitals. Funding from regional organisations such as Cancer Alliances is also required for the various phases of the evaluation. After a successful evaluation, the goal is to move on to a traditional procurement of our services.

Overall, we are making good progress in our existing dialogues while new ones are continuously being developed. The work requires perseverance and careful planning to create the best possible conditions for long-term success.

Sweden

During the vacation period, sample volumes are generally lower, mainly due to fewer healthcare visits and some clinics closing for several weeks. Customer projects and research collaborations with revenue potential also tend to develop at a slower pace during the third quarter. In September, however, sample volume returned to more normal levels and projects laying the foundation for future growth picked up again.

Development of our unique system continues, and a planned upgrade was implemented in the beginning of October. Several value-creating features strengthening our competitive position have been implemented. One example is the ability to support clinicians' reporting to national cancer registries. This feature alone has the potential to save approximately ten minutes per patient for the urologist – equivalent to two full working weeks for a urologist handling five hundred patients annually. This is another example of how we streamline workflows for our customers. In addition, we have introduced new features that reduce manual work for pathologists who perform diagnostics in our system.

The advantage of keeping system development in-house is clear. We can respond quickly to the needs of our clinicians and diagnosticians, and continuously develop the system at a pace that is difficult to match for organisations dependent on multiple external suppliers.

Organisation

During the first half of the year, we strengthened the organisation with a focus on recruiting employees for and in close proximity to the laboratory operations.

During the third quarter, we continued

to expand our sales organisation. We are strengthening our management team at Group level with a new Chief Commercial Officer, who will start in the fourth quarter. We have also initiated the recruitment of regional sales representatives in both the UK and Sweden. The timing is right for these additions, which will provide us with good conditions for running several complex customer projects in parallel.

In addition, we have further reinforced our IT management. This adds broad and important IT expertise while freeing up resources to focus on cyber security and regulatory IT issues – areas where we see increasing demands, not least in healthcare.

Data that testifies to exceptional quality and contributes to research

Several research reports on diagnostic quality, clinical research, and technology development were presented by Inify at the annual European pathology congress in Stockholm.

In a particularly significant abstract covering nearly 2,000 patient cases, we compiled data on diagnostic consistency by having external pathologists review patient cases previously diagnosed by Inify.

In only 3.6% of cases were minor changes made, none of which were considered to warrant a change to a possible treatment decision. These results testify to an exceptionally high diagnostic quality. In published studies, deviations on pathological follow-up have been reported in the range of 20–40%, although the extent and clinical significance of the deviations vary between studies.

As part of an ongoing research project with Karolinska Institute, data were presented where we, assisted by AI algorithms, studied the relationship between a specific tumour growth pattern and patient outcomes on historical data. This is

“During the quarter, we successfully delivered our services on a regular basis to University Hospital Plymouth NHS Trust.”

a typical example of how we can contribute to the development of cancer care, and the results indicate that this specific tumor growth pattern may be an important marker for aggressive disease.

Outlook

While we are currently in a period where sales growth has levelled off, we are working on several customer projects that will lay the foundation for the next growth phase. This is in line with our expectations, and we believe the main uncertainty relates to the timing of the next significant growth phase.

The challenges in healthcare and diagnostics persist and are exacerbated in some respects, increasing the burden on healthcare staff and affecting patients. The primary internal solution is to add more staff, but opportunities for this are very limited, above all due to a lack of trained personnel.

Our unique services are carefully designed to meet these challenges while contributing to the further development of care in cancer and inflammatory diseases.

We are driving a paradigm shift, and that requires perseverance. My optimism about a bright future for Inify not only remains – it grows stronger as we become increasingly established in the market.

Fredrik Palm
Chief Executive Officer

Third quarter 2026

Company history and development

Inify Laboratories AB (publ) is a Swedish company with its registered office in Stockholm, Sweden, and operates as the parent company of the Inify Laboratories group. The company was incorporated in November 2021 as a subsidiary to Context-Vision AB. Following a resolution at an extraordinary general meeting, Inify Laboratories was spun-off in February 2022 through a dividend of shares. Shortly thereafter, the company's shares were listed on Euronext Growth, Oslo.

In January 2023, a wholly owned, Swedish subsidiary was formed to support the business structure with a suitable organization. The laboratory launched its pathology services for healthcare providers in mid June 2023.

At the end of 2024, another wholly-owned subsidiary was established, based in the UK where the establishment of the business began in 2025.

The Group provides clinical diagnostic services for prostate cancer and gastro-intestinal diagnostics.

Inify Laboratories Group

The Group consists of the parent company Inify Laboratories AB (publ), with company registration number 559345-4431, the wholly owned subsidiary Inify Laboratories Nordics AB with company registration number 559416-6828, and the wholly-owned, UK subsidiary Inify Laboratories Ltd with company number 15997568.

Inify Laboratories AB

The Parent Company's business consists of research and development, management of intangible assets, Group Management and other administrative services at Group level. The company has its own development department that further develops systems and methods and conducts research in areas such as gastrointestinal diagnostics.

Inify Laboratories Nordics AB

The Swedish subsidiary's operations mainly consist of running the day-to-day laboratory and diagnostics operations in the Group's laboratory in Solna. The company also contributes to the Group's research projects and development work.

Inify Laboratories Ltd

The subsidiary in the UK was formed in October 2024. During 2025, a local laboratory for the operation of laboratory and diagnostics operations was established. The laboratory started to receive patient samples in the second quarter of 2026.

Financial development

During the third quarter of 2026, the Group's income amounted to SEK 5,238 thousand (4,991), which corresponds to an increase compared to the same quarter previous year of 5% (76%). During the first nine months the income amounted to SEK 19,168 thousand (15,772). Third-quarter revenue was affected by strengthened currencies, while sales of diagnostic services were impacted by the holiday period and declined slightly compared to the same quarter the previous year. Looking at the first nine months, however, the number of patient samples has increased. All operating income relates to diagnostic services, both within Sweden and in the UK and has been made in SEK or GBP.

Other external costs amounted to SEK -9.7 million (-7.4) in the third quarter and to SEK -28.9 million (-25.0) during the first nine months. The increase compared to the corresponding periods previous year is mainly attributable to operating and establishment costs for the subsidiary in the United Kingdom.

Personnel costs for the third quarter amounted to SEK -11.4 million (-10.7) and for the first nine months to SEK -39.6 million (-33.2). The increase in personnel costs compared to the corresponding periods last year is a natural consequence of the fact that the organization has grown and more employees have been hired. New hires have been made on an ongoing basis in all Group companies, both Swedish and foreign.

Operating results

The group's consolidated operating result in the third quarter of 2026 was SEK -20.3 million (-15.2) and in the first nine months SEK -64.2 million (-48.7). Results after financial items was SEK -19.7 million (-14.6) in the third quarter and SEK -63.0 million (-47.2) in the first nine months. EBITDA for the quarter was SEK -16.7 million (-13.8) and for the first nine months SEK -52.9 (-44.9).

Cash flow and financing

As of September 30, 2026, liquid assets for the Group amounted to SEK 72.3 million (112.2). Cash flow for the third quarter amounted to SEK -18.4 million (-17.6). Equity at the end of the period amounted to SEK 140.2 million (127.6), resulting in an equity ratio of 89.5% (83.1%).

Tangible and intangible assets

For intangible assets a depreciation period of 5 years is applied. For tangible assets a depreciation period of 5 years is also applied, with the exception of construction investments, which in the UK are depreciated over a period of 10 years.

Tangible assets at the end of the period amounted to SEK 70.4 million (25.5). The large increase in tangible assets is mainly attributable to investments in premises and machinery and equipment for the newly built British laboratory.

The intangible assets consist of the product Inify Prostate™, a decision support tool for prostate cancer diagnostics. It was originally developed by ContextVision, and was acquired and further developed by Inify Laboratories. It now serves as a fully integrated component of the in-house developed laboratory information system. Intangible assets at the end of the period amounted to SEK 0.7 million (2.7).

Inventories

Inventories are valued at the lower of cost and net realisable value. The cost of inventories is calculated by applying the principle of the first in, first out method (FIFO). Inventories at the end of the period amounted to SEK 1.9 million (1.0). The increase in inventory value is mainly attributable to purchases for the new laboratory in the UK.

Leases

Inify leases the combined office and laboratory facility on Campus Solna, which houses both the first laboratory and the Group's head office. The company also leases office space in Linköping, primarily intended for R&D activities. In addition, there are some smaller leasing commitments for vehicles, office equipment and laboratory equipment.

A lease agreement for a newly built facility in Milton Park outside Oxford was signed in May 2025, where the business in the UK is being established. A deposit of approximately SEK 2.7 million was paid to the landlord in connection to the signing of the agreement. A minor lease agreement for laboratory equipment for the subsidiary was signed in the end of 2025.

Employees

On September 30, 2026, the Group had a total of 38 (34) employees, whereof 31 (32) located in Sweden and 7 (2) in the UK. Of these, 22 (24) were employees of the parent company,

9 (8) of the Swedish subsidiary and 7 (2) of the UK subsidiary.

Incentive program

The Company's general meeting resolved on 9 May 2022 to implement a long-term incentive program for employees (the "Employee Incentive Program") and a long-term incentive program for board members (the "Board Member Incentive Program"). The long-term incentive program consists of a maximum of 3,809,660 options, divided between the Employee Incentive Program and the Board Member Incentive Program. Assuming that all options are exercised, this will correspond to a total dilution of approximately 3.5% based on the number of outstanding shares at the date of this report. Each option entitles the holder to acquire a new share or a warrant entitling to one share in the Company at an exercise price of NOK 4.80. The granted options vests over a 36-month period and may, as a general rule, only be exercised for the acquisition of new shares if the participant is still employed and the other conditions for qualified employee stock options under the Income Tax Act are met. The holder of options may exercise granted and vested options during the period from the end of the vesting period up to and including the tenth year from the date of grant.

Transactions which are eliminated by consolidation

Intra-group receivables and liabilities, income or expenses, and unrealised gains or losses arising from intra-group transactions between Group companies, are eliminated in the preparation of the consolidated financial statements. As of the balance sheet date of 30 September 2026, the parent company had group receivables and liabilities totalling SEK 108.0 million (14.0) relating to the both subsidiaries.

Related party transactions

Transactions between the parent company and its subsidiary arise naturally in the operations as, for example, premises and certain resources are shared between the companies. The group transactions for the quarter have mainly concerned interest, rents and services shared between the companies. During the third quarter, total intra-group revenues in the parent company amounted to SEK 1,145 thousand (727) and in the Swedish subsidiary to SEK 626 thousand (0). Except from above, there has been no other significant transactions with related parties.

Extraordinary General Meeting and new share issue

At an Extraordinary General Meeting on 6 December 2025, the EGM resolved on the issuance of 28,571,429 new shares through a guaranteed share issue with a total value of approximately NOK 100 million. The issue was made in two parts, where the first part, corresponding to approximately NOK 92 million, was directed to the largest shareholders and where the subscription period ended on December 16, 2025. The second part of the issue was directed to other shareholders and corresponds to approximately NOK 8 million. The subscription period for the second tranche ended on 26 January 2026. The payment date for both parts of the issue was 26 March 2026 and the newly issued shares were delivered during the period 30 March 2026 and the beginning of April.

Risks and uncertainties

The main risk factors and uncertainties for the Group include, but are not limited to, risks related to the business and industry in which the Company operates, legal and regulatory risks, risks related to the Company's financial situation and risks relating to the shares and the listing of the shares on Euronext Growth Oslo. In addition to above, the management closely monitors and regularly evaluates any risk that may arise as a result of inflation, increasing energy prices or international instability. For further details on the company's main risk factors, please refer to the Information Document published in connection with the listing on Euronext Growth in June 2022, to the Annual Report for 2025 published on April 15, 2026 and to the national prospectus published on 7 January 2025. The risks and uncertainties associated with existing operations are not expected to have changed significantly since then.

Basis of preparation

The condensed financial statements for the third quarter 2026, ending 30 September, 2026 have been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Board's general advice BFNAR 2012:1 Annual accounts and consolidated accounts ("K3"). The condensed financial statements do not include all the information and disclosures required in the annual financial statements. For detailed information, see the company's annual report for 2025, which can be found on the website.

The functional and reporting currency of the group is Swedish kronor (SEK). All amounts, unless otherwise stated, are presented in SEK thousand.

New and changed accounting principles

No new or changed accounting principles have had effect on the accounting for the period.

Subsequent events

No other significant events have occurred during the period from the balance sheet date and the issuance of this report.

Shareholder information

- Inify Laboratories ABs shares were listed on Euronext Growth Oslo on June 20, 2022 under the ticker INIFY (ISIN SE0017486103).
- As of 30 September, 2026, the Company had a total of 107,474,845 outstanding shares. All shares have equal rights and are freely transferable.
- As of 30 September, 2026, Inify had a total of 978 shareholders, of which 3 held more than 10% each of the shares.
- Detailed information about major shareholders can be found on the company's website www.inify.com.
- The 10 largest shareholders as of 30 September, 2026 are listed in the table below.

	No of shares	%	Shareholder
1	64 578 361	60.09	Gallivant S.á.r.l.
2	12 803 511	11.91	TAURI AS
3	12 289 888	11.44	MONSUN AS
4	3 556 146	3.31	BRAS KAPITAL AS
5	2 676 218	2.49	Günther-Hanssen, Sven
6	2 560 819	2.38	Danske Bank A/S
7	1 332 243	1.24	MP PENSJON PK
8	997 931	0.93	Avanza Bank AB, MEGLERKONTO
9	771 220	0.72	OLSEN, LARS EJNAR
10	432 037	0.40	SKJELBRED, RUNE
11	5 476 471	5.10	Others
	107 474 845	100.00	Total

Financial calendar

This interim report was published on the company's website on the 28 of October 2026. For further information, please visit www.inify.com.

25 February 2026	Publication of Q4 and full year 2025 Financial report
15 April 2026	Publication of Annual Report 2025
29 April 2026	Publication of Q1 2026 Financial report
20 May 2026	Annual General Meeting
26 August 2026	Publication of Q2 2026 Financial report
28 October 2026	Publication of Q3 2026 Financial report
24 February 2027	Publication of Q4 and full year 2026 Financial report

Key figures

	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Number of shares at period end	107 474 845	78 903 416	107 474 845	78 903 416	78 903 416
Average number of shares	107 474 845	62 070 083	93 189 130	62 070 083	62 070 083
Earnings per share	-0.18	-0.19	-0.59	-0.60	-0.86
Solidity (percent)	89.5%	83.1%	89.5%	83.1%	75.8%
EBITDA	-16 674	-13 827	-52 910	-44 948	-64 797

The company use some figures that are considered as Alternative Performance Measures.
Please see description under section Alternative Performance Measures and Definitions.

Consolidated income statement in summary SEK 1000

	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Net sales	4 368	4 985	16 668	15 665	22 006
Other income	870	6	2 500	107	222
Total operating income	5 238	4 991	19 168	15 772	22 228
Cost of goods	-707	-758	-2 633	-2 410	-3 403
Other external costs	-9 735	-7 350	-28 931	-24 959	-35 643
Other operating expenses	-98	-4	-943	-147	-877
Personnel costs	-11 372	-10 706	-39 571	-33 204	-47 102
Depreciation	-3 607	-1 337	-11 286	-3 714	-4 860
Operating results	-20 281	-15 164	-64 196	-48 662	-69 657
Interest income	612	519	1 222	1 466	1 850
Interest cost	0	0	-4	-6	-79
Results after financial items	-19 669	-14 645	-62 979	-47 202	-67 886
Tax	0	0	0	0	0
Net results	-19 669	-14 645	-62 979	-47 202	-67 886

Consolidated statement of comprehensive income SEK 1000

	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Net result for the period	-19 669	-14 645	-62 979	-47 202	-67 886
Other comprehensive income					
Translation differences	0	-236	0	-174	0
Total comprehensive income	-19 669	-14 881	-62 979	-47 376	-68 465

Consolidated balance sheet in summary SEK 1000

	September 30, 2026	September 30, 2025			December 31, 2025
Assets					
Intangible fixed assets	673	2 691			2 186
Tangible assets	70 441	25 489			67 399
Other financial assets	2 723	4 686			2 684
Inventories and other current assets	1 857	1 012			1 717
Current receivables	8 650	7 580			9 034
Cash and bank	72 268	112 156			57 532
Total assets	156 612	153 613			140 552
Equity and liabilities					
Equity	140 226	127 629			106 538
Other provisions	2 991	0			2 841
Current liabilities	13 404	25 984			31 173
Total equity and liabilities	156 612	153 613			140 552

Consolidated change in equity in summary SEK 1000

	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Opening balance	159 694	142 5110	106 538	33 403	33 403
Total comprehensive income for the period	-19 669	-14 881	-62 979	-47 376	-67 886
Translation differences	201	0	2 858	0	-579
Share issue	0	0	93 809	141 602	141 602
Total	140 226	127 629	140 226	127 629	106 538

Parent company income statement in summary SEK 1000

	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Net sales	1 145	727	2 834	2 142	2 947
Other income	870	6	2 500	107	222
Total operating income	2 015	733	5 335	2 249	3 169
Other external costs	-5 591	-6 267	-19 679	-21 927	-29 831
Other operating expenses	-98	-4	-936	-147	-876
Personnell costs	-6 794	-7 033	-25 949	-24 874	-34 227
Depreciation	-1 162	-1 153	-3 475	-3 459	-4 612
Operating results	-11 631	-13 725	-44 704	-48 158	-66 377
Interest income	4 573	504	10 484	1 417	1 790
Interest cost	0	0	-1	-5	-675
Results after financial items	-7 058	-13 220	-34 221	-46 746	-65 262
Group contribution	0	0	0	0	5 160
Results after group contribution	-7 058	-13 220	-34 221	-46 746	-60 102
Tax	0	0	0	0	0
Net results	-7 058	-13 220	-34 221	-46 746	-60 102

Parent company balance sheet in summary SEK 1000

	September 30, 2026	September 30, 2025		December 31, 2025
Assets				
Intangible fixed assets	673	2 691		2 186
Tangible assets	3 492	5 878		5 230
Other financial assets	244	1 119		244
Current receivables	114 586	18 474		67 978
Cash and bank	63 920	106 084		48 578
Total assets	182 914	134 247		123 546
Equity and liabilities				
Equity	-172 966	-126 734		113 378
Current liabilities	-9 948	-7 513		10 168
Total equity and liabilities	-182 914	-134 247		123 546

Parent company change in equity in summary SEK 1000

	Q3 2026	Q3 2025	9 months 2026	9 months 2025	Full year 2025
Opening balance	180 025	157 192	113 378	31 878	31 878
Total comprehensive income for the period	-7 058	-17 238	-34 221	-33 526	-60 102
Share issue	0	0	93 809	141 602	141 602
Total	172 966	139 954	172 966	139 954	113 378

Signatures

The board and the CEO certify that this interim report for the period 1 July – 30 September 2026 to the best of our knowledge, includes a fair and true review of the company's significant events, operations, financial position, results and related party transactions, and also describes the significant risks and uncertainties that the company faces. This report has not been reviewed by the company's auditors.

Stockholm, 27th October, 2026

Olof Sandén
Chairman of the board

Fredrik Palm
CEO

Martin Ingvar
Boardmember

Magne Jordanger
Boardmember

Alternative performance measures and definitions

In its financial reports, the company presents certain financial measures, including Key Figures, which are considered as Alternative Performance Measures (APM). The company believes that these figures provide useful supplementary information to investors and the company's board and management as they enable a better evaluation of the company's financial performance. Because not all companies calculate the financial figures in the same way, these are not always comparable to measures used by other companies.

Key figure	Definition	Motivation for usage
Earnings per share after tax (Return on equity)	Net result for the period divided by the number of outstanding shares at period end.	Earnings per share shows the company's results in relation to shares, and provides additional information regarding the company's profitability.
Solidity (Equity ratio)	Equity at period end as a percentage of total assets.	The equity ratio shows the company's long term ability to pay its debts and is a complement to other key figures. It helps assess the possibility of dividends.
EBITDA	Earnings before interest, taxes, depreciation and amortization. Operating profit/loss before interest, taxes, impairment and depreciation/amortization.	EBITDA shows the company's underlying development, which is valuable as an indication of the company's underlying cash-generating capacity.

Definitions

Accreditation

Accreditation is a formal recognition that an organization is competent to perform specified tasks in testing, inspection and certification.

Artificial Intelligence (AI)

Artificial Intelligence is the intelligence exhibited by machines or software.

Biopsy

A small tissue sample.

Digital Pathology

Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

Endoscopy

The use of a flexible tube with a camera, known as an endoscope, to inspect the inside of different organs. An endoscope that is used to investigate the stomach is called a gastroscope and an endoscope for examination of the colon is called a colonoscope.

Gastroenterology

An examination of the gastro-intestinal tract with an endoscope. Using the endoscope it is possible to take tissue samples and remove pre-cancerous lesions.

GI

Gastro-intestinal.

Histopathology

Examination of tissue specimens to study the visible manifestations of disease.

Image analysis

Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

LIS

Laboratory Information System

Machine Learning

Machine learning is the study of computer algorithms that automatically improve through experience.

MDT

Multidisciplinary Team Meeting is a meeting of professionals from one or more clinical disciplines who together make decisions regarding recommended treatment of individual patients.

NHS

National Health Service.

Pathology report

A medical report provided to the referring physician that describes the characteristics of a piece of tissue, blood, or body organ that has been removed from the body.

Referral/request

Order from a physician for a diagnostic examination of a specimen of tissue or other samples from a patient.

Specimen

Part of a human body (e.g., Biopsy Specimen) or organ that is to be examined by the laboratory.



Inify
Laboratories

© 2026 Inify Laboratories

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations. Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.